공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

췌장의 전이성 선암 : 파이프라인 리뷰

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 08월 상품 코드 269899
페이지 정보 영문 217 Pages
가격
US $ 2,000 ₩ 2,260,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,521,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,781,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


췌장의 전이성 선암 : 파이프라인 리뷰 Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016
발행일 : 2016년 08월 페이지 정보 : 영문 217 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

전이성 췌암이란 췌장에 기인하여 그 후 간, 폐 및 뼈 등 신체의 다른 부위로 퍼지는 형태의 암입니다. 증상에는 등의 통증, 체중 감소, 식욕 감퇴, 황달, 암색뇨 및 옅은 점도색의 변 등이 있습니다. 구역질, 구토 및 전신 권태감을 경험할 가능성도 있습니다. 발병 요인에는 가족력, 흡연, 만성 췌장염 및 당뇨병 등을 들 수 있습니다. 치료에는 외과 수술, 화학 요법 및 방사선 요법이 있습니다.

췌장의 전이성 선암(Metastatic Adenocarcinoma of The Pancreas) 치료제의 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

췌장의 전이성 선암 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품

기업에서 개발중인 제품

대학/기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Array BioPharma Inc.
  • Axcentua Pharmaceuticals AB
  • Berg LLC
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • CTI BioPharma Corp.
  • CytRx Corporation
  • Eleison Pharmaceuticals LLC
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Incyte Corporation
  • Merrimack Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • Phoenix Biotechnology, Inc.
  • Plexxikon Inc.
  • Sanofi
  • Targovax AS

치료제 평가

  • 단독요법(Monotherapy) 제품별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • aldoxorubicin hydrochloride
  • AXP-10711
  • BI-853520
  • binimetinib
  • Cellular Immunotherapy for Cancer
  • Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer
  • ceritinib
  • CRS-207
  • glufosfamide
  • GS-5745
  • GSK-2256098
  • ibrutinib
  • INCB-52793
  • indoximod
  • irinotecan hydrochloride
  • LGK-974
  • MesoCART
  • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology
  • napabucasin
  • paclitaxel
  • palbociclib
  • PBI-05204
  • pelareorep
  • plerixafor
  • PLX-7486
  • PRI-724
  • ribociclib
  • SGT-53
  • sonidegib phosphate
  • TG-01
  • tosedostat
  • ubidecarenone
  • ulixertinib
  • Vaccine for Oncology

최근의 파이프라인 동향

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 16.05.10

Summary:

Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016', provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
  • The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Adenocarcinoma of The Pancreas Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview
    • Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis
  • Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies
  • Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies
  • Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes
  • Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Aduro BioTech, Inc.
    • Array BioPharma Inc.
    • Axcentua Pharmaceuticals AB
    • Berg LLC
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • CTI BioPharma Corp.
    • CytRx Corporation
    • Daiichi Sankyo Company, Limited
    • Eleison Pharmaceuticals LLC
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Incyte Corporation
    • MabVax Therapeutics Holdings, Inc.
    • Merrimack Pharmaceuticals, Inc.
    • NewLink Genetics Corporation
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Pfizer Inc.
    • Phoenix Biotechnology, Inc.
    • Targovax ASA
  • Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aldoxorubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXP-10711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-853520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceritinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glufosfamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-5745 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2256098 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HuMab-5B1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-52793 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • indoximod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MesoCART - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • napabucasin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-05204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pelareorep - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRI-724 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGT-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosedostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ubidecarenone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulixertinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Adenocarcinoma of The Pancreas - Dormant Projects
  • Metastatic Adenocarcinoma of The Pancreas - Discontinued Products
  • Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones
    • Featured News & Press Releases
      • Aug 04, 2016: Merrimack Provides Update on ONIVYDE
      • Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas
      • Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
      • May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016
      • Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations
      • Jan 25, 2016: Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
      • Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission
      • Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax ASA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2016
  • Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016
  • Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q